Clinical trials: Disease Free Survival
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung…
- Trial name
- SOLID (NCT07698990)
- Testing
- Anatomic Segmentectomy, Anatomic Lobectomy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shanghai Chest Hospital
Anxiety Disorder, Cognitive/Functional Effects
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical…
- Conditions
- Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression
- Trial name
- CHALLENGE (NCT00819208)
- Testing
- exercise intervention, counseling intervention, educational intervention
- Where
- 47 sites in United States, Australia and 4 more
- Volunteers
- 889 people
- Sponsor
- Canadian Cancer Trials Group
Residual Tumor, Disease-free Survival
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
To assess the feasibility, Residual Tumor, complication rate and survival of totally laparoscopic primary cytoreduction in carefully selected patients with Advanced Ovarian Cancer, compared with abdominal primary cytoreduction in…
- Conditions
- Residual Tumor, Disease-free Survival, Overall Survival
- Trial name
- NCT02980185
- Testing
- Laparoscopic primary cytoreduction
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Università degli Studi dell'Insubria
Gastric Cancer
Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients
Since it is not uncertain about efficacy of combination therapy with PSK and TS-1 in gastric cancer, in this study, we compare efficacy and safety of postoperative adjuvant therapy using TS-1 or TS-1+PSK in the stage II or III…
- Trial name
- TMOG-GC01 (NCT00687843)
- Testing
- Tegafur-gimeracil-oteracil potassium (TS-1), Krestin (PSK)
- Where
- Japan
- Volunteers
- 480 people
- Sponsor
- Tokyo Metropolitan Oncology Group
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe)
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Background: Cancers that spread into the thin tissue lining your lungs (pleura) cause serious illness. They often recur when removed.
- Conditions
- Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant
- Trial name
- NCT05375825
- Testing
- Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Progression-free Survival
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who…
- Trial name
- NCT00944918
- Testing
- fulvestrant, anastrozole, exemestane
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
This study aims to test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression…
- Trial name
- MITO-8 (NCT00657878)
- Testing
- stealth liposomal doxorubicin, carboplatin, paclitaxel
- Where
- 40 sites in Belgium, Germany and 1 more
- Volunteers
- 215 people
- Sponsor
- National Cancer Institute, Naples
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
At present, it is recommended to continue immunotherapy until progression or unacceptable toxicity. However, only a minority of patients benefits from a durable response and most see the disease progress despite several months of…
- Trial name
- TRAILOCLORI01 (NCT05111197)
- Testing
- SRT, Immunotherapy
- Where
- 5 sites in France
- Volunteers
- 112 people
- Sponsor
- Institut Cancerologie de l'Ouest
Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Title: A Study of Cadonilimab Combined with Capecitabine After Surgery for Mixed Type Liver Cancer This is a phase II clinical trial.
- Trial name
- NCT07243951
- Testing
- Cadonilimab, Capecitabine
- Volunteers
- 75 people
- Sponsor
- Shanghai Zhongshan Hospital
Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010…
- Trial name
- TELESTO (NCT00940602)
- Testing
- Deferasirox
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
This cohort study is divided into two parts: Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general…
- Conditions
- Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer, Microsatellite Instability-High Colorectal Cancer, Stage II Colorectal Cancer
- Trial name
- RESIST (NCT07829081)
- Testing
- Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care
- Where
- 3 sites in Switzerland
- Volunteers
- 234 people
- Sponsor
- University Hospital, Basel, Switzerland
Carcinoma, Non-Small-Cell Lung
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of endostatin combined with Docetaxel in advanced Non-Small-Cell Lung Carcinoma (NSCLC) patients failure to first-line or second-line chemotherapy.
- Trial name
- NCT01192230
- Testing
- Endostatins, Docetaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Progression Free Survival, Overall Survival
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment.
- Conditions
- Progression Free Survival, Overall Survival, Maintenance
- Trial name
- NCT05477797
- Testing
- Ixazomib DX/Lenalidomide DX
- Where
- China
- Volunteers
- 420 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Endometrial Carcinoma
UTOLA: UTerin OLAparib
This is a phase IIB, national, randomized, double-blinded, comparative, multi-center study, to assess the efficacy of Olaparib as maintenance after a platinum based chemotherapy in patients with Advanced or metastatic endometrial…
- Trial name
- UTOLA (NCT03745950)
- Testing
- Olaparib Oral Capsule
- Where
- 36 sites in France
- Volunteers
- 147 people
- Sponsor
- ARCAGY/ GINECO GROUP
Multiple Myeloma
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
Multiple myeloma is a malignant incurable hematological disease where survival has been significantly improved by high-dose melphalan with autologous stem cell support (ASCT) in younger patients.
- Trial name
- NCT00417911
- Testing
- bortezomib
- Where
- 20 sites in Denmark, Finland and 3 more
- Volunteers
- 400 people
- Sponsor
- Nordic Myeloma Study Group
Melanoma Stage I, Melanoma Stage III
Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin
The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery.
- Conditions
- Melanoma Stage I, Melanoma Stage III, Melanoma Stage II, Skin Melanoma
- Trial name
- ATSMAIN (NCT07671495)
- Testing
- Surgical resection, Adjuvant Radiotherapy, interferon alfa
- Volunteers
- 278 people
- Sponsor
- MIPO Clinic
Prostate Cancer, Brachytherapy
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease.
- Conditions
- Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-N (NCT07426094)
- Testing
- Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy